Acadia Pharmaceuticals Inc., of San Diego, said the FDA completed a postmarketing review and reaffirmed the risk-benefit profile of Parkinson's disease psychosis drug Nuplazid (pimavanserin). The agency found no new or unexpected safety risks associated with the drug in its analysis, which was conducted following reports of a number of deaths and other serious adverse events in patients taking the drug.